40+ results for "AI"
ONLYOFFICE 10.0 brings AI tools, modular apps, and stronger security to its open-source office suite
SINGAPORE , Oct. 10, 2026 -- ONLYOFFICE presents the major autumn update 10.0 with context-aware AI tools directly in the editors, new modular Apps, and a significant security upgrade. Around 50 new features and more than 1,000 fixes for the online, desktop, and mobile editors. AI that understands your documents, in every editor ONLYOFFICE 10.0 puts context-aware AI inside the document, spreadsheet, presentation, and PDF editors. A dedicated AI tab with built-in chat lets teams draft, summarize, translate, clean and format without leaving the file or copying content into a separate tool.
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms a
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance system Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologic
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetings Date: October 12
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasis Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis Real-world research examines the role long-term topical corticosteroid use plays in the c
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York. Conference Details: Panel Discussion: Immunology & Inflammation Therapies Presente
TestMu AI Positioned as a Leader in the 2026 Gartner® Magic Quadrant™ for Agentic Software Quality Assurance Platforms
Evaluation Based on Completeness of Vision and Ability to Execute NOIDA, India , Oct. 9, 2026 -- TestMu AI , the Full-Stack Agentic AI Quality Engineering platform, announced it has been positioned as a Leader in the 2026 Gartner Magic Quadrant for Agentic Software Quality Assurance Platforms. A complimentary copy of this research report is available [ here ]. As software delivery shifts toward agentic workflows, TestMu AI continues to advance end-to-end quality engineering through agentic testing and scalable cloud execution infrastructure. The platform provides independent verification, nondeterministic agent evaluation, and governance capabilities that allow enterprise teams to transition smoothly into agentic software delivery while maintaining existing browser and device testing environments.
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 23, 2026. The press release, and its accompanying financial exhibits, will also be
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-tolerated Clinical findings and preclinical mechanistic evidence support FASN inhibition as a novel oral therapeutic approach targeting key aspects of acne pathogenesis AURORA U.S. Phase 3 trial screening patients, with sites activated and IRB approvals in place
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring required The approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and s
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomize
HackerOne Report Highlights Challenges of 'Exposure Debt': NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Oct. 9, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on October 9th HackerOne released its 10 th annual Security Research Report this week. The report found that the backlog of validated, unresolved vulnerabilities grew by 131% in two years. Exposure Debt is at the focus of the report, which HackerOne defines as the growing gap between what organizations find and what they can fix. CEO Kara Sprague will join NYSE Live to dive deeper into the findings and discuss the impact of AI across cybersecurity. Zeta Global held its Zeta Live 26 event in New York City on Thursday. Zeta Global (NYSE: ZETA) announced that it teamed up with Fireworks to develop the Athena Inference Model. CEO David Steinberg spoke to the heightened enthusiasm for Zeta Global s work and the evolution of Athena in an interview that will air on NYSE Live. The major averages will look to bounce back as investors monitor the AI trade. A revenue report from OpenAI impacted market activity on Thursday. Elevated Treasury yields and oil prices continue to drive economic sentiment.
KONE Inaugurates India's First Digital Experience Centre in Pune to Advance Digital Innovation
New Centre showcases how AI, connectivity, data and digital solutions are transforming customer experiences and enabling smarter, more connected buildings PUNE, India , Oct. 9, 2026 -- KONE, a global leader in the elevator and escalator industry, today inaugurated India s first KONE Digital Experience Centre (DEC) in Pune, marking an important milestone in its digital transformation journey and commitment to creating exceptional customer experiences through technology, data and innovation. The Centre was jointly inaugurated by Jussi Herlin, Executive Vice Chair, KONE; Philippe Delorme, President and CEO, KONE along with Nandan Nilekani, Co-founder and Chairman of the Board, Infosys.
Chandigarh University Hosts National Incubator & Capital Summit and ISBACON 2026, Bringing 400 Incubators, 80 Investors & 100 Startups Together to Strengthen India's Startup Ecosystem
Chandigarh University Launches C-Hub Incubator of Incubators as National Consortium to Take Indian Startups from Ideas to Market CHANDIGARH, India , Oct. 9, 2026 -- Aimed at strengthening access to early-stage investment for startups by connecting India s incubation institutions with investors, industry and policymakers, Chandigarh University brought together more than 400 incubator institutions from more than 20 States and Union Territories, over 100 startups, 80 investors and more than 60 government, policy and industry delegates on a single platform at Incubator & Capital Summit 2026 and ISBACON 2026.
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone 1 First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage II
MIDEA COMPLETES THE ACQUISITION OF ESAOTE
Midea Group marks its commitment to healthcare and innovation by completing the acquisition of Esaote GENOA, Italy , Oct. 9, 2026 -- Esaote S.p.A., a leader in the medical imaging sector, announces the completion of the controlling stake acquisition of its share capital by Midea the Chinese global technology group headquartered in the district of Shunde, Foshan. The transaction is aimed at fostering synergies between Esaote and Midea s Healthcare Division to increase international competitiveness. Esaote will be part of Midea Healthcare and will continue to operate as an independent global medical equipment company, headquartered in Genoa, Italy, with R&D and manufacturing facilities in Italy and the Netherlands.
Charmacy Milano Celebrates 6th Birthday With Carnival Sale and Rs 1.8 Lakh Creator Hunt
Charmacy Milano Carnival Sale Begins October 12: Unlock Flat 20% OFF, 10% Cashback, and 9 Days of Daily Arcade Rewards Mumbai-based vegan, cruelty-free beauty brand hosts a 9-day festive event on charmacyworld.com from October 12-20. MUMBAI, India , Oct. 9, 2026 -- Mumbai-based vegan and cruelty-free colour cosmetics brand Charmacy Milano will mark its sixth birthday on October 18 by launching the Charmacy Carnival , a nine-day festive event running from October 12 to 20 on charmacyworld.com . The celebration will feature Flat 20% OFF, 10% Cashback, daily arcade rewards and a Rs 1.8 lakh creator hunt , along with a live makeup masterclass series.
Hisense Brings AI Companion Suite to Life with a Social Kitchen
QINGDAO, China , Oct. 9, 2026 -- Hisense, a leading brand in global consumer electronics and home appliances, is bringing its vision of Innovating a Brighter Life into the heart of the home with the new PureSmart Duo Series a refrigerator series designed as the intelligent center of the kitchen and now being rolled out across global markets. Building on the AI Companion Suite introduced at IFA 2026, Hisense is extending its vision of AI beyond appliances to create connected experiences across the home. Through the ConnectLife platform, the PureSmart Duo Series brings people, appliances and experiences together, making AI a more natural part of everyday life.
IMC 2026: From Connectivity to Deployment at Scale, Fibocom Strengthens Its IoT Presence in India
NEW DELHI , Oct. 9, 2026 -- Fibocom (300638.SZ; 0638.HK), a leading global provider of wireless communication modules and AI solutions, presented its latest portfolio at India Mobile Congress 2026, as growing adoption of 5G, energy digitalization and connected mobility creates new demand for IoT deployment across India. At the show, Fibocom highlighted applications spanning wireless broadband, energy, vehicle and asset management. Its FWA portfolio included 5G modules as well as CPE, ODU and MiFi solutions, while smart meters, vehicle tracking devices and EV battery trackers demonstrated how cellular connectivity is moving deeper into vertical applications.
SGS WINS SAF SUPPLY CHAIN EXCELLENCE AWARD AT INDIA SAF CONCLAVE & AWARDS 2026
NEW DELHI , Oct. 9, 2026 -- We are proud to announce that we have been recognized with the SAF Supply Chain Excellence Award Testing, Inspection, Verification & Quality Assurance at the India SAF Conclave & Awards 2026, held on September 29 at Bharat Mandapam, New Delhi. This prestigious recognition highlights our contribution to strengthening quality, integrity, transparency and confidence across the Sustainable Aviation Fuel (SAF) value chain through its testing, inspection, verification and quality assurance capabilities.
Embark and Tavant Partner to Enable AI-Ready Global Capability Centres in India
The partnership brings together Embark s end-to-end GCC setup and operations capabilities with Tavant s AI, data and digital engineering expertise to help enterprises build, scale and transform GCCs in India BENGALURU, India , Oct. 9, 2026 -- Embark , a premier, fully integrated service provider dedicated to accelerating the establishment and expansion of Global Capability Centres (GCCs) in India, and Tavant , a leading platform-powered AI transformation specialist, today announced a strategic partnership to help global enterprises design, build, operate and transform GCCs in India.
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement. Under the agreement, Rua will import, distribute and sell PharmAla’s pharmaceutical-grade LaNeo™ MDMA in New Zealand. The agreement follows Medsafe’s approval, on 4 September 2026, of two psy
Precision Neuroscience Unveils a New Map of the Human Nervous System
A uniquely large dataset spanning cortex, brainstem, and spinal cord in 70 patients—released as the Precision system passes its 100th patient implant NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced a new manuscript describing a growing atlas of the human central nervous system, built from high-resolution surface electrophysiology recordings in 70 patients across twelve academic medical centers. The atlas is designed to grow with every pa
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Comp
Iantrek Expands Clinical Evidence for Bio-Interventional Ophthalmic Surgery Across Trabecular and Uveoscleral Outflow Pathways
Six-month data on a new bio-reinforced canaloplasty procedure show 37% IOP reduction; new findings on bio-reinforced cyclodialysis to be presented at AAO 2026 WHITE PLAINS, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a company pioneering bio-interventional ophthalmic surgery (BIOS), today announced topline six-month results from a first-in-human, investigator-initiated study evaluating bio-reinforced canaloplasty targeting the trabecular outflow pathway. Together with two upcoming pre
Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 third quarter earnings conference call on Thursday, November 5, 2026, at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/e
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene
Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response ENIGMA-TRS 1 enrollment expected to be completed by mid-October; topline 12-week data expected in Q1 2027 ENIGMA-TRS 2 enrollment continuing outside the U.S., with additional clinical sites being added as planned FDA clinical hold remains in place at U.S. study centers; Newron intends to respond upon thorough r
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week PISCATAWAY, N.J. and SANTA CLARA, Calif. , Oct. 8, 2026 / PRNewswire / -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest , a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript s wet lab validation and data generation capabilities and NVIDIA s accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.
Hexaware Becomes an Anthropic Preferred Partner, Bringing Claude to the Core of Its AI-native Platforms
Multi-year partnership combines Anthropic s Claude with Hexaware s Zerovity and AgentVerse platforms to deliver outcome-based AI services for enterprises MUMBAI, India and LONDON and ISELIN, N.J., Oct. 8, 2026 -- Hexaware Technologies (NSE: HEXT), a global provider of IT services and solutions, today announced a multi-year strategic partnership with Anthropic. Under the partnership, Hexaware becomes a Preferred Partner in Anthropic s Claude Partner Network. The partnership brings Claude to the core of two Hexaware platforms: Zerovity , its AI-native engineering platform, and AgentVerse , its agent build and governance platform with more than 600 pre-built agents. Hexaware will use Claude to deliver outcome-based services across IT operations and software engineering, as enterprise clients increasingly buy results rather than effort.
Banks Think They're Ready for Tomorrow's Fraud. Feedzai's Survey Suggests Otherwise
Feedzai s new Fraud Readiness Index finds financial institutions are spending heavily on AI, but disconnected data and manual work are holding fraud teams back. NEW YORK and LISBON, Portugal , Oct. 8, 2026 -- Banks and fintechs are confident they re ready for the next wave of fraud, but the evidence suggests they re overestimating themselves. In Feedzai s latest research report, Confidence & Capability: The Feedzai Fraud Readiness Index 2026 which surveyed more than 1,000 senior fraud leaders across 12 countries financial institutions rated their own fraud readiness at an average score of 80.2 out of 100. But when measured against their actual capabilities across data, AI, intelligence sharing, and fraud team operations, the average dropped to 66.9.
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON , Oct. 8, 2026 -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc. , (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.
Helfie Signs MOU with Homa Bay Kenya Ministry of Health for TB and Hypertension Screening Pilot
Population-scale pilot will target 100,000 of Homa Bay s most vulnerable people across five sub-counties. MELBOURNE, Australia , Oct. 8, 2026 -- Helfie AI ( Helfie ), an AI-powered preventive network transforming global healthcare, today announced it has signed a Memorandum of Understanding (MOU) with Kenya s Homa Bay County Ministry of Health to pilot a population-scale health screening and monitoring program. The pilot will target 100,000 of the county s most vulnerable people across five sub-counties of Homa Bay, supporting early screening and monitoring for tuberculosis (TB) and hypertension. The program will run entirely on the user s mobile device and reflects almost nine months of on-the-ground planning and collaboration between Helfie, Homa Bay s Ministry of Health and the county s population health team.
MAYBELLINE NEW YORK LAUNCHES "TOGETHER WE'RE BRAVE" CAMPAIGN FOR WORLD MENTAL HEALTH DAY
Maybelline s Brave Together Platform Introduces New Campaign That Spotlights the Power of Connection and Support in Mental Health Journeys NEW YORK , Oct. 8, 2026 -- Ahead of World Mental Health Day on October 10, Maybelline New York unveiled Together We re Brave, the latest chapter of Brave Together, the brand s global mental health program that has helped more than four million people access free one-to-one support worldwide. The campaign spotlights the unbreakable bonds that help people navigate anxiety, depression and other mental health challenges and celebrates the loved ones who stand beside them when they need it most.
2026 World Fire Congress Communities of Practice Unite Global Fire Service Leaders Around Shared Solutions for The Future of Fire Safety
Powered by UL Research Institutes, the Communities of Practice offer a sustained mechanism to share knowledge, align on emerging risks, and rapidly translate research across borders COLUMBIA, Md. , Oct. 8, 2026 -- Following the biennial gathering of the world s fire leaders at the World Fire Congress, UL Research Institutes Fire Safety Research Institute is powering the ongoing Communities of Practice (CoPs) to advance solutions for the most pressing global fire safety issues. The structured and sustained CoPs will accelerate progress through monthly thematic sessions, shared governance, robust information distribution and direct integration of frontline research.
Dreame Technology Announces Great Indian Festival 2026 Sale with Its Best-Ever Prices on Smart Home and Personal Care Products
Unmatched offers on select robotic vacuums, wet and dry vacuum cleaners, cordless stick vacuums, and its personal care range on Amazon NEW DELHI , Oct. 8, 2026 -- With the Amazon Great Indian Festival just around the corner, Dreame Technology, a global leader in smart home innovation, is bringing its smart home and personal care range to consumers with exclusive offers on Amazon India. Starting today , the sale will feature attractive deals across Dreame s portfolio of robotic vacuums, wet and dry vacuum cleaners, cordless stick vacuums and grooming solutions, giving consumers an opportunity to upgrade their everyday routines with smart technology. The products will also be available at the same festive prices on the Dreame India website , Croma and Reliance Retail.
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of Bio Usawa Biotech Botswana (Pty) Ltd, marking an important milestone in the company’s mission to build a self-sustaining biotechnology ecosystem across Africa and expand access to safe, effective, and affordable biologic medicines. The Botswana subsidiary expands Bio Usawa’s interna